TrialDrug design, development and therapy2025
Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial).
Ruoyang Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.